EP3634470A4 - Glucose sensitive compositions for drug delivery - Google Patents

Glucose sensitive compositions for drug delivery Download PDF

Info

Publication number
EP3634470A4
EP3634470A4 EP18810805.4A EP18810805A EP3634470A4 EP 3634470 A4 EP3634470 A4 EP 3634470A4 EP 18810805 A EP18810805 A EP 18810805A EP 3634470 A4 EP3634470 A4 EP 3634470A4
Authority
EP
European Patent Office
Prior art keywords
drug delivery
sensitive compositions
glucose sensitive
glucose
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18810805.4A
Other languages
German (de)
French (fr)
Other versions
EP3634470A1 (en
Inventor
Zhen GU
Jicheng YU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
University of California
Original Assignee
North Carolina State University
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University, University of California filed Critical North Carolina State University
Publication of EP3634470A1 publication Critical patent/EP3634470A1/en
Publication of EP3634470A4 publication Critical patent/EP3634470A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP18810805.4A 2017-06-02 2018-06-04 Glucose sensitive compositions for drug delivery Pending EP3634470A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762514099P 2017-06-02 2017-06-02
PCT/US2018/035799 WO2018223114A1 (en) 2017-06-02 2018-06-04 Glucose sensitive compositions for drug delivery

Publications (2)

Publication Number Publication Date
EP3634470A1 EP3634470A1 (en) 2020-04-15
EP3634470A4 true EP3634470A4 (en) 2021-03-10

Family

ID=64455020

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18810805.4A Pending EP3634470A4 (en) 2017-06-02 2018-06-04 Glucose sensitive compositions for drug delivery

Country Status (4)

Country Link
US (1) US11096893B2 (en)
EP (1) EP3634470A4 (en)
CN (1) CN111315399B (en)
WO (1) WO2018223114A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220249533A1 (en) * 2019-06-03 2022-08-11 Duke University Compositions and methods for bone repair and bone health
CN114748433B (en) * 2022-05-12 2023-09-29 苏州大学 Anti-inflammatory and antioxidant pharmaceutical composition and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100029545A1 (en) * 2008-08-04 2010-02-04 Sumerlin Brent S Boronic acid-containing block copolymers for controlled drug delivery

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3018463B2 (en) * 1989-10-19 2000-03-13 日本油脂株式会社 Glucose-responsive drug-releasing complex
KR930001305B1 (en) 1989-10-19 1993-02-25 니뽕 유우시 가부시끼가이샤 Polymer compleres of sugar response type
JP3087293B2 (en) * 1990-09-13 2000-09-11 日本油脂株式会社 Sugar-responsive polymer complex
JP2874309B2 (en) * 1990-09-13 1999-03-24 日本油脂株式会社 Sugar-responsive polymer complex
JP2000086534A (en) * 1999-10-20 2000-03-28 Nof Corp Sugar-responding polymer complex
WO2006102762A1 (en) * 2005-04-01 2006-10-05 Mcmaster University Glucose responsive microgels
WO2009026328A2 (en) * 2007-08-21 2009-02-26 Immune Disease Institute, Inc. Methods of delivery of agents to leukocytes and endothelial cells
EP2680822B1 (en) * 2011-03-02 2022-02-23 Sensulin, LLC Vesicle compositions
CN103874482B9 (en) * 2011-10-07 2017-03-01 国立大学法人鸟取大学 Liposome complex
CA2756621C (en) * 2011-10-26 2020-07-14 Michael Serpe Gel assembly
EP2727597A1 (en) * 2012-11-06 2014-05-07 Centre National de la Recherche Scientifique (CNRS) Glucose responsive hydrogel comprising pba-grafted hyaluronic acid (ha)
EP3219787B1 (en) * 2014-11-11 2020-01-01 Denka Company Limited Agent for preserving biological component, and method for recovering biological component
KR102624501B1 (en) * 2015-04-21 2024-01-11 노쓰 캐롤라이나 스테이트 유니버시티 Glucose-responsive insulin delivery system using hypoxia-sensitive nanocomposites

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100029545A1 (en) * 2008-08-04 2010-02-04 Sumerlin Brent S Boronic acid-containing block copolymers for controlled drug delivery

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AKIRA MATSUMOTO ET AL: "Glucose-Responsive Polymer Gel Bearing Phenylborate Derivative as a Glucose-Sensing Moiety Operating at the Physiological pH", BIOMACROMOLECULES, vol. 5, no. 3, 15 April 2004 (2004-04-15), pages 1038 - 1045, XP008159372, ISSN: 1525-7797, [retrieved on 20040415], DOI: 10.1021/BM0345413 *
DOMINTE TARUS ET AL: "Readily Prepared Dynamic Hydrogels by Combining Phenyl Boronic Acid- and Maltose-Modified Anionic Polysaccharides at Neutral pH", MACROMOLECULAR RAPID COMMUNICATIONS, vol. 35, no. 24, December 2014 (2014-12-01), pages 2089 - 2095, XP055440663, ISSN: 1022-1336, DOI: 10.1002/marc.201400477 *
M JO ET AL: "Preparation and Characterization of Glucose-Responsive Hyaluronate-Based Nanoparticles", TISSUE ENGINEERING PART A, vol. 21, 1 September 2015 (2015-09-01), pages S-362, XP055765420, ISSN: 1937-3341, DOI: 10.1089/ten.tea.2015.5000.abstracts *
RUJIANG MA ET AL: "Phenylboronic Acid-Based Complex Micelles with Enhanced Glucose-Responsiveness at Physiological pH by Complexation with Glycopolymer", BIOMACROMOLECULES, vol. 13, no. 10, 2012, pages 3409 - 3417, XP055510591, ISSN: 1525-7797, DOI: 10.1021/bm3012715 *
See also references of WO2018223114A1 *
SERRE K ET AL: "EFFICIENT PRESENTATION OF MULTIVALENT ANTIGENS TARGETED TO VARIOUS CELL SURFACE MOLECULES OF DENDRITIC CELLS AND SURFACE IG OF ANTIGEN-SPECIFIC B CELLS", THE JOURNAL OF IMMUNOLOGY, vol. 161, no. 11, December 1998 (1998-12-01), pages 6059 - 6067, XP000882910, ISSN: 0022-1767 *
SUNG HAN KIM ET AL: "pH-Responsive NIR-Absorbing Fluorescent Polydopamine with Hyaluronic Acid for Dual Targeting and Synergistic Effects of Photothermal and Chemotherapy", BIOMACROMOLECULES, vol. 18, no. 6, 8 May 2017 (2017-05-08), pages 1825 - 1835, XP055414817, ISSN: 1525-7797, DOI: 10.1021/acs.biomac.7b00267 *
WILLIAM L. A. BROOKS ET AL: "Synthesis and Applications of Boronic Acid-Containing Polymers: From Materials to Medicine", CHEMICAL REVIEWS, vol. 116, no. 3, 10 February 2016 (2016-02-10), pages 1375 - 1397, XP055414948, ISSN: 0009-2665, DOI: 10.1021/acs.chemrev.5b00300 *
ZHONGMING WU ET AL: "Phenylboronic acid grafted chitosan as a glucose-sensitive vehicle for controlled insulin release", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 100, no. 6, June 2011 (2011-06-01), pages 2278 - 2286, XP055049781, ISSN: 0022-3549, DOI: 10.1002/jps.22463 *

Also Published As

Publication number Publication date
EP3634470A1 (en) 2020-04-15
CN111315399B (en) 2024-05-10
US11096893B2 (en) 2021-08-24
WO2018223114A1 (en) 2018-12-06
CN111315399A (en) 2020-06-19
US20200085743A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
EP3565550A4 (en) Pharmaceutical compositions comprising meloxicam
EP3294212A4 (en) Drug delivery from hydrogels
EP3463228A4 (en) Intraocular drug delivery
EP3368084A4 (en) Pharmaceutical compositions for transmucosal delivery
EP3621621A4 (en) Pharmaceutical compositions comprising meloxicam
EP3302265A4 (en) Drug delivery capsule
EP3265064A4 (en) Drug delivery device
EP3378482A4 (en) Antitumor drug delivery formulation
EP3452075A4 (en) Ophthalmic pharmaceutical composition
EP3532131A4 (en) Wearable drug delivery device
ZA202001044B (en) Drug delivery composition
EP3723750A4 (en) Drugs and compositions for ocular delivery
EP3664885A4 (en) Transdermal drug delivery system
AU2018302170A1 (en) Pharmaceutical compositions comprising entrectinib
EP3621656A4 (en) Ocular drug delivery formulation
EP3638311A4 (en) Polymeric paste compositions for drug delivery
EP3643353A4 (en) Drug delivery robot
EP3581183A4 (en) Tumor-treating pharmaceutical composition
EP3479828A4 (en) Drug composition for parenteral administration
EP3658123A4 (en) High drug loading pharmaceutical compositions
EP3213746A4 (en) Pharmaceutical composition for oral administration comprising taxane
EP3583943A4 (en) Pharmaceutical composition
EP3801703A4 (en) Tissue integrated drug delivery system
EP3302443A4 (en) Mechano-sensitive microcapsules for drug delivery
EP3154524A4 (en) Extended-release drug delivery compositions

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0038280000

Ipc: A61K0047690000

A4 Supplementary search report drawn up and despatched

Effective date: 20210208

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/69 20170101AFI20210202BHEP

Ipc: A61P 3/10 20060101ALI20210202BHEP

Ipc: A61K 38/28 20060101ALI20210202BHEP

Ipc: A61K 9/51 20060101ALI20210202BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230526

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240404